Dermatology News

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.

The FDA has announced a proposed rule that would require manufacturers of talc-containing cosmetic products to use standardized testing methods to identify the presence of asbestos, a known carcinogen.

A healthy 5-year-old boy, whose only problem had been mild-to-moderate seborrheic dermatitis, is taken to his provider with the complaint of a sore on his left lower eyelid.

Healio spoke to the president of the American Academy of Dermatology after the organization issued a letter to the editor of The Atlantic with “serious concerns” over its article entitled “Against sunscreen absolutism.”

The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.

A healthy, athletic 17-year-old male was seen by his primary physician with complaints of the gradual onset of a lesion under his right great toenail.

DermaSensor has announced the publication of its study showcasing the ability of its elastic scattering spectroscopy device to assist primary care clinicians in identifying skin cancer, according to a press release.

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.

Deucravacitinib is superior to placebo for improving response across all domains of minimal disease activity criteria in patients with psoriatic arthritis at 16 weeks, according to data published in Rheumatology.